Gesynta Pharma reaches 50% patient enrollment milestone in Phase 2 endometriosis trial Vietnam Investment Review - VIR
Endometriosis is a chronic, estrogen-dependent inflammatory disease sustained by aberrant angiogenesis and progressive fibrosis. We evaluated the therapeutic efficacy of human dental pulp-derived mesenchymal stem cells (DP-MSCs) in a surgically …
After manufacturing changes, the safety and tolerability of the progesterone vaginal ring (PVR) was compared to findings from the similarly designed phase 3 trial. This prospective, open-label, single-arm, multi-center U.S. …
Endometriosis (EMs) is a prevalent gynecological disorder characterized by the ectopic growth of functional endometrial tissue, and its fibrotic pathology represents a primary contributor to chronic pain and infertility in …
Endometriosis is a chronic estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age and characterized by ectopic endometrial-like tissue growth. Although traditionally considered a benign gynecological condition, increasing …
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS
Karyopharm completes endometrial cancer trial enrollment Investing.com
Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire